Jazz Pharmaceuticals JAZZ Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationTaxCreditsResearch.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount?
- Jazz Pharmaceuticals (JAZZ) reported effective income tax rate reconciliation, tax credit, research, amount of $8.83M in Q4 2025.
- How has Jazz Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount changed year-over-year?
- Jazz Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount decreased by 45.9% year-over-year, from $16.31M to $8.83M.
- What is the long-term trend for Jazz Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's effective income tax rate reconciliation, tax credit, research, amount has grown at a 3.3% compound annual growth rate (CAGR), from $31.07M to $35.33M.
- What does effective income tax rate reconciliation, tax credit, research, amount mean?
- The total dollar value of tax credits claimed for research and development activities.
- How do you interpret effective income tax rate reconciliation, tax credit, research, amount?
- Higher values indicate more effective utilization of R&D tax incentives, which lowers the effective tax rate.
- How does effective income tax rate reconciliation, tax credit, research, amount compare across companies?
- Widely used by R&D-intensive firms; comparable across the pharmaceutical and technology sectors.